An interventional study of Nutritional supplementation standardized formula. and Placebo in ADHD - Attention Deficit Disorder With Hyperactivity, sponsored by Rabin Medical Center. Recruiting at 1 site in Israel. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Rabin Medical Center · Not applicable, Interventional, and Treatment
Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel — 9 open to participants now, 10 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Israel.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, this one is the 20th largest by planned enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2021, is one of 38 with no phase, and was the 66th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 296 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →9 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel are open now. Recruiting first, the newest first:
Adina Maeir · Sites in Israel
Women only · Healthy volunteers
Hebrew University of Jerusalem · Sites in Israel
Ages 18–60
Ben-Gurion University of the Negev · Sites in Israel
Ages 18–65
Loewenstein Hospital · Sites in Israel
Ages 15–18 · Men only
University of Haifa · Sites in Israel
Ages 20–60 · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: Up to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4 · Phase 4 4
First in 2000; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 46 across the 61 interventional studies, 60 across the 23 observational. Of the 45 that completed or were terminated, 7 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 85 have an industry lead sponsor. The 10 most frequent:
Rabin Medical Center is the lead sponsor of 393 studies on the registry; 30 are open to participants now.
Rabin Medical Center has 3 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07105475Ben-Gurion University of the NegevTreatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation | 2027-09-01 |
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed study is a double blind, randomized, placebo controlled study. The aim of the study is to evaluate the effect of nutritional formula supplementation on growth of prepubertal children treated with stimulants medications of ADHD.
70 Participants treated with stimulants medications of ADHD will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the study. Randomization will be stratified according to gender.
Participants in the intervention groups will be treated with the study formula and participants in the control group will be treated with a placebo low caloric formula (Powder added to water). The study will continue for 6 months of intervention versus active placebo, with additional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the active study supplement.
In addition, 30 prepubertal healthy siblings will be recruited to the study in order to compare baseline eating and physical activity patterns of ADHD children treated with stimulants to their healthy untreated siblings at the same age range. Participants' siblings will only complete once the nutritional and physical activity questionnaire and report height and weight measurements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Dietary Supplement: Nutritional supplementation standardized formula.
Low caloric formula (Powder added to waster) without added vitamins and minerals
Dietary Supplement: Placebo
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Low caloric formula (powder added to water) without added vitamins and minerals
height standard deviation score (SDS)
Time frame: at 6 months
weight standard deviation score
Time frame: at 6 months
BMI SDS
Time frame: at 6 months
Fat Mass
Time frame: at 6 months
Lean body mass
Time frame: at 6 months
Muscle mass
Time frame: at 6 months
Change in dietary patterns measured by Child Eating Behaviour Questionnaire
Time frame: At 6 months
Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale
Time frame: at 6 months
Change in physical activity patterns measured by physical activity questionnaire
Time frame: at 6 months
height SDS
Time frame: at 12 months
Weight SDS
Time frame: at 12 months
BMI SDS
Time frame: at 12 months
Fat mass
Time frame: at 12 months
Lean body mass
Time frame: at 12 months
Muscle mass
Time frame: at 12 months
Change in dietary patterns measured by Child Eating Behaviour Questionnaire
Time frame: at 12 months
Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale
Time frame: at 12 months
Change in physical activity measured by physical activity questionnaire
Time frame: at 12 months
Started Jul 2021 (actual). Primary completion is estimated for Jul 2024, 36 months after the start.
Of 479 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 36 months is above that.
Counting every sponsor, half of 510 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →